Intravitreal Injection
A procedure to deliver medication directly into the eye, commonly used for macular degeneration, diabetic eye disease, and vein occlusions.
Intravitreal injection is a procedure where medication is injected directly into the vitreous cavity—the gel-filled space inside the eye. This delivers drugs to the retina at high concentrations, treating conditions like macular degeneration, diabetic macular edema, and retinal vein occlusions. Millions of these injections are performed annually worldwide, making it one of the most common eye procedures.
Key Takeaways
- Medication delivered directly into the eye
- Treats macular degeneration, diabetic eye disease, vein occlusions
- Quick procedure—typically under 5 minutes
- Done in office—no operating room needed
- Very safe when performed by experienced providers
- May need repeated injections (monthly or as needed)
Medications Used
Anti-VEGF Agents (Most Common)
Block vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage. See our anti-VEGF injections guide for detailed drug information, mechanisms, and outcomes.
Common Anti-VEGF Drugs:
- Aflibercept (Eylea)
- Ranibizumab (Lucentis)
- Bevacizumab (Avastin)—off-label but widely used
- Faricimab (Vabysmo)
- Brolucizumab (Beovu)
Corticosteroids
Reduce inflammation and swelling:
- Dexamethasone implant (Ozurdex)—slow-release pellet
- Triamcinolone acetonide
- Fluocinolone implant (Iluvien)
Other Medications
- Antibiotics (for endophthalmitis)
- Antivirals (for viral retinitis)
- Ocriplasmin (Jetrea) (for vitreomacular traction)
Conditions Treated
Age-Related Macular Degeneration (AMD)
- Anti-VEGF injections are primary treatment
- Dramatically improved outcomes
- Converted previously blinding condition to manageable one
Diabetic Eye Disease
- Diabetic macular edema (DME)
- Proliferative diabetic retinopathy
- First-line treatment for center-involving DME
Retinal Vein Occlusions
- Central retinal vein occlusion
- Branch retinal vein occlusion
- Treats associated macular edema
Other Conditions
- Myopic choroidal neovascularization
- Uveitic macular edema
- Radiation maculopathy
- Some retinal infections
The Injection Procedure
Preparation
Before the injection:
- Eye is numbed with anesthetic drops or gel
- Antiseptic (povidone-iodine, betadine) applied to kill bacteria
- Eyelid speculum placed to keep eye open
- You look in a specific direction
During the Injection
- The needle is inserted through the white of the eye (sclera)
- Enters the vitreous cavity
- Medication is injected
- Needle is withdrawn
- Antiseptic reapplied
Total time: approximately 30 seconds to 2 minutes for the injection itself
What You'll Feel
- Pressure sensation (most common)
- Brief stinging from antiseptic
- Some patients feel nothing
- Rarely, brief sharp sensation
Most patients find the anticipation worse than the actual injection.
While the idea of an eye injection sounds frightening, most patients report minimal discomfort. The eye is thoroughly numbed, and the procedure is very quick.
After the Injection
Immediately After
- Vision may be blurry (from numbing drops, antiseptic, or air bubbles)
- Eye may be red where needle entered
- May see floaters temporarily
- Pressure sensation for a few hours is normal
First Few Days
Normal experiences:
- Mild redness at injection site
- Scratchy sensation
- Floaters (especially small bubbles)
- Slight discomfort
When to call your doctor:
Contact your eye doctor immediately if you experience:
- Significant pain (not just mild discomfort)
- Worsening vision
- Increasing redness
- Light sensitivity
- Discharge from the eye
These could indicate infection (endophthalmitis), which requires emergency treatment.
Activity Restrictions
- Most normal activities can resume immediately
- Some doctors advise avoiding swimming for a day
- Avoid rubbing the eye
- Generally no other significant restrictions
Risks and Complications
Common (Usually Minor)
- Subconjunctival hemorrhage (red spot on white of eye)—harmless, resolves
- Floaters—usually temporary
- Mild discomfort
- Transient elevated eye pressure
Rare but Serious
Endophthalmitis (Infection Inside Eye):
- Risk approximately 1 in 2,000 to 1 in 5,000 injections
- Reduced by strict sterile technique
- Requires emergency treatment
- Can cause vision loss if delayed
Retinal Detachment:
- Very rare
- Symptoms: flashes, floaters, curtain over vision
Other Rare Complications:
- Cataract (from needle touching lens)
- Persistent elevated eye pressure
- Bleeding inside eye
- Stroke or heart attack (with anti-VEGF—very rare)
Treatment Schedules
Loading Phase
Many protocols start with monthly injections:
- Build up drug levels in the eye
- Gain control of the disease
- Typically 3 or more monthly injections
Maintenance Phase
After initial control, various approaches:
Fixed Interval:
- Injections at regular intervals (e.g., every 8 weeks)
- Predictable but may over- or under-treat
Treat and Extend:
- Gradually increase interval if stable
- Decrease if disease recurs
- Personalized approach
PRN (As Needed):
- Inject only when disease recurs
- Requires frequent monitoring visits
- May result in worse outcomes than regular treatment
How Long?
- Treatment is often ongoing (years)
- Some patients achieve stability and can extend or stop
- Others need continued injections
- Depends on condition and individual response
What to Expect Over Time
Typical Journey
- Diagnosis: Condition requiring injection identified
- Loading phase: Monthly injections for 3+ months
- Assessment: Check response, adjust plan
- Maintenance: Ongoing treatment as needed
- Monitoring: Regular visits even if injections spaced out
Realistic Expectations
- Most patients maintain or improve vision
- Complete cure is uncommon—management is the goal
- Treatment burden is real (frequent visits)
- Benefits outweigh risks for most patients
Frequently Asked Questions
Does the injection hurt?
Most patients experience minimal discomfort—usually just pressure or a brief stinging. The eye is thoroughly numbed before the injection. Many patients say it's much better than they expected.
Will I see the needle?
You'll see a blur or shadow but won't see the needle clearly. Looking away as instructed keeps your vision directed away from the injection site.
How long does the injection take?
The actual injection takes seconds. The entire appointment, including preparation and post-injection check, typically takes 15-30 minutes.
How many injections will I need?
This varies widely by condition and individual response. Some patients need monthly injections for years; others can eventually extend to every few months. Your doctor will develop a personalized treatment plan.
Can I drive after the injection?
Most patients can drive after the effects of the dilating drops wear off (a few hours). Vision may be blurry initially from the drops and procedure. If in doubt, arrange transportation.
Why do I need injections so often?
The medications work locally in the eye and wear off over weeks. Regular injections maintain therapeutic drug levels. Researchers are developing longer-lasting treatments.
Are there alternatives to injections?
For most conditions treated with intravitreal injections, injections are the most effective option. Laser treatment may be an adjunct or alternative in some cases. Discuss options with your doctor.
What if I miss an injection?
Contact your doctor to reschedule as soon as possible. Missing injections can allow the disease to progress. If significant time has passed, your doctor may adjust the treatment plan.
Can both eyes be injected at the same visit?
Many doctors do inject both eyes in a single visit if both are being treated. Some prefer separate visits to reduce the (very small) risk of bilateral infection. Discuss the approach with your doctor.
References
Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Discuss intravitreal injection therapy with your retina specialist.
Sources:
- American Academy of Ophthalmology. Intravitreal Injections.
- Avery RL, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34(Suppl 12):S1-S18.
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
- National Eye Institute. Age-Related Macular Degeneration.
